Cite
Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.
MLA
Xie, Ying, et al. “Down-Regulating Nrf2 by Tangeretin Reverses Multiple Drug Resistance to Both Chemotherapy and EGFR Tyrosine Kinase Inhibitors in Lung Cancer.” Pharmacological Research, vol. 186, Dec. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.phrs.2022.106514.
APA
Xie, Y., Feng, S., He, F., Yan, P.-Y., Yao, X.-J., Fan, X.-X., Leung, E. L.-H., & Zhou, H. (2022). Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer. Pharmacological Research, 186, N.PAG. https://doi.org/10.1016/j.phrs.2022.106514
Chicago
Xie, Ying, Sen-ling Feng, Fang He, Pei-Yu Yan, Xiao-Jun Yao, Xing-Xing Fan, Elaine Lai-Han Leung, and Hua Zhou. 2022. “Down-Regulating Nrf2 by Tangeretin Reverses Multiple Drug Resistance to Both Chemotherapy and EGFR Tyrosine Kinase Inhibitors in Lung Cancer.” Pharmacological Research 186 (December): N.PAG. doi:10.1016/j.phrs.2022.106514.